← FDA DRUG APPROVALS

FDA ANDA · ANDA219585

ZINC SULFATE

Sponsor: ASPIRO

APPLICATION
ANDA219585
TYPE
ANDA
ORIGINAL APPROVAL
2025-05-01
LATEST ACTION
2025-05-01
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ZINC SULFATEPrescription
ZINC SULFATE EQ 25MG BASE/5ML (EQ 5MG BASE/ML) · SOLUTION · INTRAVENOUS
ZINC SULFATEPrescription
ZINC SULFATE EQ 30MG BASE/10ML (EQ 3MG BASE/ML) · SOLUTION · INTRAVENOUS
ZINC SULFATEPrescription
ZINC SULFATE EQ 10MG BASE/10ML (EQ 1MG BASE/ML) · SOLUTION · INTRAVENOUS

Approval history

2025-05-01UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →